ArticleChemistry & biodiversity2026
Antibacterial and Antibiotic Potentiation Activities of Selected Australian Terminalia spp. Against Gastrointestinal Pathogens.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Terminalia spp. (family Combretaceae) are widely used to treat a wide variety of ailments, including bacterial infections. The antibacterial activities of multiple Terminalia spp. have been verified experimentally. Several studies have reported inhibitory activity for Terminalia catappa L. against some bacteria, including a limited number of gastrointestinal pathogens. In contrast, the growth-inhibitory effects of several native Australian species against gastrointestinal pathogens have not yet been evaluated. This study screens the bacterial growth inhibition activity of T. catappa, T. microcarpa, T. muelleri, and T. canescens leaf extracts against a panel of gastrointestinal bacterial pathogens. Solvents with different polarities were used to extract different complements of phytoconstituents from the dried leaves. The T. canescens methanol extract displayed noteworthy activity against A. hydrophila and B. cereus (960 µg/mL). In contrast, none of the ethyl acetate extracts prepared from any species tested displayed bacterial growth inhibitory activity. Notably, combinations of the Terminalia spp. extracts and selected conventional antibiotics yielded 15 synergistic, 59 additive, 79 non-interactive, and 29 antagonistic interactions. All the plant extracts were deemed to be nontoxic in human dermal fibroblast cell line assays, except the T. muelleri and T. microcarpa methanol extracts and the T. canescens water extract.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.